Abstract
Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.
| Original language | English |
|---|---|
| Pages (from-to) | 517-518 |
| Number of pages | 2 |
| Journal | Cancer Treatment Reports |
| Volume | 70 |
| Issue number | 4 |
| State | Published - 1 Jan 1986 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
